:max_bytes(150000):strip_icc()/GettyImages-2178012636-44572e0fb5bd4412a0b07f795b71c4c8.jpg?w=1920&resize=1920,1267&ssl=1 "Allurion Stock Triples on Plan to Test Gastric Balloon With Obesity Drugs | Global News Avenue")
Allurion Stock Triples on Plan to Test Gastric Balloon With Obesity Drugs
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2178012636-44572e0fb5bd4412a0b07f795b71c4c8.jpg)
Key points
- Allurion Technologies said it plans to use the key components of popular weight loss drugs to test its gastric balloon to see if the combination can improve the patient’s muscle quality.
- The company pointed out that people treated with GLP-1 will lose muscle quality, while those who accept their products maintain muscle quality.
- The news of the news has doubled, but it has been greatly reduced in the past year.
ALLURION Technologies Stock (channelOn Friday, the manufacturer of the ALLURION gastric balloon weight loss device seemed to use the booming obesity drug market.
The company announced a research to check whether its gastric balloon is combined with Novo Nordisk (Novo Nordisk’s)Non -governmental organization) Wegovy and Eli Lilly (Liberal) Mounjaro can improve the muscle quality and overall body component of patients.
The company pointed out that previous research showed that people who used GLP-1 therapy “” showed a reduction in lean meat by about 40 %, which is part of the overall weight decrease. “It added that other studies showed that other studies showed that using the ALLURION gastric airbag People while maintaining muscle quality (increased in some cases).
Dr. Shantanu GAUR, the founder and CEO of the founder and CEO, explained that for GLP-1 users, the decline in lean quality and muscle waste is a major issue. “Our early data shows that we may have a powerful tool to achieve more metabolic metabolism Dr. GAUR in Health “Balloon-GLP-1 combination is successful, and it may become a golden standard for obesity care. ”
This news made investors in Allurion Technologies since watching the stock sinking. Since the trading in the summer of 2023, they quickly watched their stock sinking. It has been 85 % over the past year.
TradingView
:max_bytes(150000):strip_icc()/GettyImages-2178012636-44572e0fb5bd4412a0b07f795b71c4c8.jpg?w=1200&resize=1200,0&ssl=1&description=Allurion+Stock+Triples+on+Plan+to+Test+Gastric+Balloon+With+Obesity+Drugs+%7C+Global+News+Avenue){kind=link}